Effects of acetyl-L-carnitine and oxfenicine on aorta stiffness in diabetic rats
Kuo-Chu Chang
Department of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan
Search for more papers by this authorChuen-Den Tseng
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Search for more papers by this authorShao-Chun Lu
Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, Taiwan
Search for more papers by this authorJin-Tung Liang
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
Search for more papers by this authorMing-Shiou Wu
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Search for more papers by this authorMing-Shian Tsai
Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan
Search for more papers by this authorKwan-Lih Hsu
Department of Internal Medicine, E-Da Hospital and Department of Nursing, I-Shou University, Kaohsiung, Taiwan
Search for more papers by this authorKuo-Chu Chang
Department of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan
Search for more papers by this authorChuen-Den Tseng
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Search for more papers by this authorShao-Chun Lu
Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, Taiwan
Search for more papers by this authorJin-Tung Liang
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
Search for more papers by this authorMing-Shiou Wu
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Search for more papers by this authorMing-Shian Tsai
Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan
Search for more papers by this authorKwan-Lih Hsu
Department of Internal Medicine, E-Da Hospital and Department of Nursing, I-Shou University, Kaohsiung, Taiwan
Search for more papers by this authorAbstract
Eur J Clin Invest 2010; 40 (11): 1002–1010
Background We compared the haemodynamic and metabolic effects of acetyl-L-carnitine (one of the carnitine derivatives) and of oxfenicine (a carnitine palmitoyltransferase-1 inhibitor) in streptozotocin-induced diabetes in male Wistar rats.
Materials and methods Diabetes was induced by a single tail vein injection of 55 mg kg−1 streptozotocin. The diabetic animals daily treated with either acetyl-L-carnitine (150 mg kg−1 in drinking water) or oxfenicine (150 mg kg−1 by oral gavage) for 8 weeks,were compared with the untreated age-matched diabetic controls. Arterial wave reflection was derived using the impulse response function of the filtered aortic input impedance spectra. Thiobarbituric acid reactive substances (TBARS) measurement was used to estimate malondialdehyde (MDA) content.
Results Oxfenicine, but not acetyl-L-carnitine, increased total peripheral resistance in diabetes, which paralleled its elevation in plasma levels of free fatty acids. By contrast, acetyl-L-carnitine, but not oxfenicine, resulted in a significant increase in wave transit time and a decrease in wave reflection factor, suggesting that acetyl-L-carnitine may attenuate the diabetes-induced deterioration in systolic loading condition for the left ventricle. This was in parallel with its lowering of MDA/TBARS content in plasma and aortic walls in diabetes. Acetyl-L-carnitine therapy also prevented the diabetes-related cardiac hypertrophy, as evidenced by the reduction in ratio of the left ventricular weight to body weight.
Conclusion Acetyl-L-carnitine, but not oxfenicine, attenuates aortic stiffening and cardiac hypertrophy, possibly through its decrease of lipid oxidation-derived MDA/TBARS in the rats with insulin deficiency.
References
- 1 Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14(Suppl 5): S1–85.
- 2 Avogaro A, De Kreutzenberg SV, Negut C, Tiengo A, Scognamiglio R. Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 2004; 93: A13–6.
- 3 Ding A, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006; 291: H1489–506.
- 4 Vitale C, Collins P. Optimization of cardiac metabolism in diabetes mellitus. Curr Pharm Des 2008; 14: 2537–50.
- 5 Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34: 25–33.
- 6 Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002; 105: 1861–70.
- 7 Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634–41.
- 8 Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med 2004; 25: 455–73.
- 9 Marciani P, Lindi C, Marzo A, Arrigoni Martelli E, Cardace G, Esposito G. L-carnitine and carnitine ester transport in the rat small intestine. Pharmacol Res 1991; 23: 157–62.
- 10 Liu J, Head E, Kuratsune H, Cotman CW, Ames BN. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann NY Acad Sci 2004; 1033: 117–31.
- 11 Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002; 27: 621–36.
- 12 Stephens TW, Higgins AJ, Cook GA, Harris RA. Two mechanisms ptoduce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J 1985; 227: 651–60.
- 13 Vik-Mo H, Mjos OD, Neely JR, Maroko PR, Ribeiro LG. Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium. Am Heart J 1986; 111: 1048–54.
- 14 Dichtl W, Nilsson L, Goncalves I, Ares MP, Banfi C, Calara F et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 1999; 84: 1085–94.
- 15 Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939–45.
- 16 Staiger K, Staiger H, Weigert C, Haas C, Haring HU, Kellerer M. Saturated, but not unsaturated, fatty acids induce apoptosis of human coronary artery endothelial cells via nuclear factor-kappaB activation. Diabetes 2006; 55: 3121–6.
- 17 Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100: 1230–9.
- 18 De Kreutzenberg SV, Crepaldi C, Marchetto S, Calò L, Tiengo A, Del Prato S et al. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab 2000; 85: 793–8.
- 19 Dimmeler S, Haendeler J, Zeiher AM. Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipidol 2002; 13: 531–6.
- 20 Oram JF, Bornfeldt KE. Direct effects of long-chain non-esterified fatty acids on vascular cells and their relevance to macrovascular complications of diabetes. Front Biosci 2004; 9: 1240–53.
- 21 Slatter DA, Paul RG, Murray M, Bailey AJ. Reactions of lipid-derived malondialdehyde with collagen. J Biol Chem 1999; 274: 19661–9.
- 22 Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 2000; 43: 550–7.
- 23 Milnor WR. Hemodynamics. Baltimore: Williams & Wilkins Co., 1989.
- 24 Chang KC, Hsu KL, Tseng YZ. Effects of diabetes and gender on mechanical properties of the arterial system in rats: aortic impedance analysis. Exp Biol Med 2003; 228: 70–8.
- 25 Nichols WW, O’Rourke MF. McDonald’s blood flow in arteries. London: Arnold, 2005.
- 26 Mitchell GF, Pfeffer MA, Westerhof N, Pfeffer JM. Measurement of aortic input impedance in rats. Am J Physiol 1994; 267 ( Heart Circ Physiol 36): H1907–15.
- 27 Liu A, Brin KP, Yin FCP. Estimation of total arterial compliance: An improved method and evaluation of current methods. Am J Physiol 1986; 251 ( Heart Circ Physiol 20): H588–600.
- 28 Laxminarayan S, Sipkema P, Westerhof N. Characterization of the arterial system in the time domain. IEEE Trans Biomed Eng 1978; 25: 177–84.
- 29 Westerhof N, Sipkema P, Vanden Bos GC, Elzinga G. Forward and backward waves in the arterial system. Cardiovasc Res 1972; 6: 648–56.
- 30 Okabe H, Uji Y, Nagashima K, Noma A. Enzymic determination of free fatty acids in serum. Clin Chem 1980; 26: 1540–3.
- 31 Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovas Dis 2005; 15: 316–28.
- 32 Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 2007; 380: 50–8.
- 33 Beuge JA, Aust SD. Microsomal lipids peroxidation. Methods Enzymol 1978; 52: 302–10.
- 34 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.
- 35 Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, Delghingaro-Augusto V et al. A role for the malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes 2004; 53: 1007–19.
- 36 Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25: 487–96.
- 37 Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006; 98: 596–606.
- 38 Kanter JE, Johansson F, LeBoeuf RC, Bornfeldt KE. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res 2007; 100: 769–81.
- 39 Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006; 116: 1071–80.
- 40 Shanmugam N, Figarola JL, Li Y, Swiderski PM, Rahbar S, Natarajan R. Proinflammatory effects of advanced lipoxidation end products in monocytes. Diabetes 2008; 57: 879–88.
- 41 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615–25.
- 42 Greenwald SE. Ageing of the conduit arteries. J Pathol 2007; 211: 157–72.
- 43
O’Rourke MF,
Avolio AP,
Nichols WW.
Left ventricular-systemic arterial coupling in humans and strategies to improve coupling in disease states. In: FCP Yin, editor. Ventricular/Vascular Coupling. New York: Springer-Verlag, 1987:pp
1–19.
10.1007/978-1-4613-8634-6_1 Google Scholar
- 44 Okere IC, Chandler MP, McElfresh TA, Rennison JH, Kung TA, Hoit BD et al. Carnitine palmitoyl transferase-I inhibition is not associated with cardiac hypertrophy in rats fed a high-fat diet. Clin Exp Pharmacol Physiol 2007; 34: 113–9.
- 45 Cox RH. Three-dimensional mechanics of arterial segments in vitro methods. J Appl Physiol 1974; 36: 381–4.
